Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects ; volume:24 ; number:6 ; day:14 ; month:8 ; year:2024 ; pages:743-752 ; date:11.2024
American journal of cardiovascular drugs ; 24, Heft 6 (14.8.2024), 743-752, 11.2024
- Urheber
-
Bruggen, Folkert H. van
Haas, Esther C. de
Zuidema, Sytse U.
Luijendijk, Hendrika J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40256-024-00668-y
- URN
-
urn:nbn:de:101:1-2501192121379.132749731823
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bruggen, Folkert H. van
- Haas, Esther C. de
- Zuidema, Sytse U.
- Luijendijk, Hendrika J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany